Skip to content
PICO Portalanswers from OpenAlex

Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy

PaperCitations, authors & open-access status

Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy is a paper indexed in PICO Portal from OpenAlex.

How many citations does Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy have?

PICO Portalcitation count

Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy has 245 citations in the OpenAlex counts PICO Portal stores.

When was Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy published?

PICO Portalyear

Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy has 1999 year in the PICO Portal index.

What is the open-access status of Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy?

PICO Portaloa status

Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy has closed oa status in the PICO Portal index.

What is the DOI of Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy?

PICO Portaldoi

The DOI for Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy is on the source record.

What is the PMID of Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy?

PICO Portalpmid

The PMID for Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy is on the source record.

What is the OpenAlex record for Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy?

PICO Portalopenalex

The OpenAlex for Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial